PT2349342T - Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água - Google Patents

Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água

Info

Publication number
PT2349342T
PT2349342T PT09752930T PT09752930T PT2349342T PT 2349342 T PT2349342 T PT 2349342T PT 09752930 T PT09752930 T PT 09752930T PT 09752930 T PT09752930 T PT 09752930T PT 2349342 T PT2349342 T PT 2349342T
Authority
PT
Portugal
Prior art keywords
understanding
water soluble
soluble polymer
low water
blood factors
Prior art date
Application number
PT09752930T
Other languages
English (en)
Portuguese (pt)
Inventor
Siekmann Juergen
Rottensteiner Hanspeter
Turecek Peter
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PT2349342T publication Critical patent/PT2349342T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT09752930T 2008-10-17 2009-10-16 Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água PT2349342T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10642408P 2008-10-17 2008-10-17

Publications (1)

Publication Number Publication Date
PT2349342T true PT2349342T (pt) 2018-10-26

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09752930T PT2349342T (pt) 2008-10-17 2009-10-16 Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água

Country Status (20)

Country Link
US (4) US20100099616A1 (enExample)
EP (3) EP3437661A1 (enExample)
JP (2) JP5785872B2 (enExample)
KR (2) KR101929641B1 (enExample)
AU (1) AU2009305612B2 (enExample)
BR (1) BRPI0920259A8 (enExample)
CA (1) CA2738679A1 (enExample)
CY (1) CY1120921T1 (enExample)
DK (1) DK2349342T3 (enExample)
ES (1) ES2692172T3 (enExample)
HR (1) HRP20181454T1 (enExample)
HU (1) HUE039906T2 (enExample)
LT (1) LT2349342T (enExample)
MX (1) MX2011004085A (enExample)
NZ (1) NZ592688A (enExample)
PL (1) PL2349342T3 (enExample)
PT (1) PT2349342T (enExample)
SI (1) SI2349342T1 (enExample)
SM (1) SMT201800486T1 (enExample)
WO (1) WO2010045568A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー/エス 低減されたvwf結合を有する因子viii分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US20130183280A1 (en) * 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
GB201910190D0 (en) * 2012-04-16 2019-08-28 Cantab Biopharmaceuticals Patents Ltd Optimised subsutaneous therapeutic agents
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第viii因子製剤
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第viii因子の複合体形成能に関する情報の取得方法および試薬キット
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
BR0311978A (pt) * 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
MXPA05006688A (es) 2002-12-19 2006-02-22 Nektar Therapeutics Al Corp Conjugados de polimero con una variante de cianovirina.
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
JP2006523211A (ja) * 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 viii
AU2007333049B2 (en) * 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.

Also Published As

Publication number Publication date
AU2009305612A1 (en) 2010-04-22
KR20160103173A (ko) 2016-08-31
ES2692172T3 (es) 2018-11-30
CA2738679A1 (en) 2010-04-22
HUE039906T2 (hu) 2019-02-28
HRP20181454T1 (hr) 2018-12-14
EP2349342B1 (en) 2018-06-27
KR20110071012A (ko) 2011-06-27
SMT201800486T1 (it) 2018-11-09
EP2349342A1 (en) 2011-08-03
US20120076749A1 (en) 2012-03-29
BRPI0920259A8 (pt) 2017-09-19
KR101929641B1 (ko) 2018-12-14
US20160199503A1 (en) 2016-07-14
WO2010045568A1 (en) 2010-04-22
EP3437661A1 (en) 2019-02-06
JP2012505917A (ja) 2012-03-08
EP3620177A1 (en) 2020-03-11
MX2011004085A (es) 2011-09-27
NZ592688A (en) 2012-12-21
DK2349342T3 (en) 2018-10-08
BRPI0920259A2 (pt) 2016-01-05
PL2349342T3 (pl) 2019-01-31
LT2349342T (lt) 2018-10-10
JP5785872B2 (ja) 2015-09-30
US20190160178A1 (en) 2019-05-30
AU2009305612B2 (en) 2015-05-21
SI2349342T1 (sl) 2018-10-30
CY1120921T1 (el) 2019-12-11
US20100099616A1 (en) 2010-04-22
JP2015110676A (ja) 2015-06-18

Similar Documents

Publication Publication Date Title
BRPI0919884A2 (pt) cateter de perfusão de oclusão
BRPI0915302A2 (pt) artigo absorvente que compreende um campo de design
BRPI0923882A2 (pt) identificando um dispositivo com fonte de alimentação própria conectado com um dispositivo médico
BRPI0919058A2 (pt) indicador biológico independente
SMT201800486T1 (it) Fattori sanguigni modificati comprendenti un grado basso di polimero solubile in acqua
EP2405954A4 (en) Surgical fluid management system
BRPI0906922A2 (pt) Válvula de alta pressão
BRPI0912326A2 (pt) análogos de acetaminofeno hidrossolúveis
EP2328648A4 (en) TRANSPARENT CATHETER MOUNTING SYSTEM
EP2263082A4 (en) ANALYSIS OF BLOOD VISCOSITY
BRPI0920392A2 (pt) reservatório de sangue
DK2291368T3 (da) Substitueret gamma-lactam som terapeutisk middel
EP2341974A4 (en) CATHETER ARRANGEMENT
DE602007000542D1 (de) Blutdruckmesser
BRPI0819257A2 (pt) monitor de pressão sanguínea
BRPI0821540A2 (pt) Tecido renal encapsulado
BRPI0916060A2 (pt) "interconector para fluidos"
EP2274172A4 (en) Fluid container
DK2141382T3 (da) Hydraulikventil
DK2205288T3 (da) Sterilisationsindikator
BRPI0915880A2 (pt) turbina hidráulica
BRPI0915466A2 (pt) freio automático
FR2937857B1 (fr) Membrane chirurgicale antiadherence
EP2207837A4 (en) PHOTOSENSITIVE CROSS-LINKED POLYMER
DE112009001725A5 (de) Hydraulische Bremsanlage